Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis
Go back to Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis| Regeneron (NASDAQ: REGN) | Delayed: 835.59 -5.25 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $840.84 | 52 Week High | $592.36 | |||
| Open | $831.70 | 52 Week Low | $325.35 | |||
| Day High | $837.27 | P/E | 219.31 | |||
| Day Low | $830.56 | EPS | $3.81 | |||
| Volume | 22,565 | |||||
| Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) | Delayed: 57.85 -0.35 (0.6%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.20 | 52 Week High | $35.13 | |||
| Open | $57.94 | 52 Week Low | $28.10 | |||
| Day High | $58.04 | P/E | N/A | |||
| Day Low | $57.85 | EPS | $0.00 | |||
| Volume | 14,671 | |||||

